



BML531241

Laboratory Investigation Report

Name	: Mr. SRDAN VIROVAC	Ref No.	: 37308
DOB	: 29/05/1989	Sample No.	: 2502544239
Age / Gender	: 35 Y / Male	Collected	: 26/02/2025 18:00
Referred by	: CITICARE MEDICAL CENTER	Registered	: 26/02/2025 23:21
Centre	: CITICARE MEDICAL CENTER	Reported	: 27/02/2025 00:10

ENDOCRINOLOGY

Test	Result	Flag	Unit	Reference Range	Methodology
ESTRADIOL (E2)	17.5		pg/mL	11.3 - 43.2 Please note update. Source: Roche	ECLIA

INTERPRETATION NOTES :

Refer to Interpretation Table for Female Reference Range:

FEMALE	REFERENCE RANGE (pg/mL)
Tanner Stage I (>14 days and prepubertal) (Mean Age: 7.1 years)	Undetectable - 20
Tanner Stage II (Mean Age: 10.5 years)	Undetectable - 24
Tanner Stage III (Mean Age: 11.6 years)	Undetectable - 60
Tanner Stage IV (Mean Age: 12.3 years)	15 - 85
Tanner Stage V (Mean Age: 14.5 years)	15 - 350
Follicular Phase	20.5 - 233
Mid Cycle	60.4 - 602
Luteal Phase	51.1 - 222
First Trimester	154 - 3243
Second Trimester	1561 - 21280
Third Trimester	8525 - > 30000
Post Menopause	< 5
Please note update in reference range. Source: Roche; Mayo Clinic Laboratories for Tanner Stage	

Refer to Interpretation Table for Male Reference Range:

1 to 14 days: Estradiol levels in newborns are very elevated at birth but will fall to prepubertal levels within a few days.

TANNER STAGE MALE	REFERENCE RANGE (pg/mL)
Stage I (>14 days and prepubertal)(Mean Age: 7.1 years)	Undetectable - 13
Stage II (Mean Age: 12.1 years)	Undetectable - 16
Stage III (Mean Age: 13.6 years)	Undetectable - 26
Stage IV (Mean Age: 15.1 years)	Undetectable - 38
Stage V (Mean Age: 18 years)	10 - 40

Dr. Adley Mark Fernandes
M.D (Pathology)
Pathologist

Gyoma V. Shah
Dr. Vyoma V Shah
M.D (Pathology)
Clinical Pathologist

This is an electronically authenticated report

Page 1 of 4

ANJUMOL D V
ANJUMOL D V
Laboratory Technologist
Printed on: 27/02/2025 00:15

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.





BML531241

Laboratory Investigation Report

Name	: Mr. SRDAN VIROVAC	Ref No.	: 37308
DOB	: 29/05/1989	Sample No.	: 2502544239
Age / Gender	: 35 Y / Male	Collected	: 26/02/2025 18:00
Referred by	: CITICARE MEDICAL CENTER	Registered	: 26/02/2025 23:21
Centre	: CITICARE MEDICAL CENTER	Reported	: 27/02/2025 00:10

ENDOCRINOLOGY

Test	Result	Flag	Unit	Reference Range	Methodology
------	--------	------	------	-----------------	-------------

Increased level is seen in early puberty, tumors in the ovaries or testes, gynecomastia, hyperthyroidism, cirrhosis of liver.
Decreased level is seen in menopause, Turner syndrome, ovarian failure, polycystic ovarian syndrome (PCOS), depleted estrogen production, which can be caused by low body fat, hypopituitarism, hypogonadism.

TESTOSTERONE (TOTAL)	41.1	H	nmol/L	8.64 - 29	ECLIA
-----------------------------	-------------	----------	--------	-----------	-------

Please note change in method and reference range.
Source: Roche IFU.

INTERPRETATION NOTES :

Tanner Stage Interpretation Table (Source:Roche IFU):

Tanner Stage	Reference Ranges (Male)	Reference Ranges (Female)
Tanner Stage I (> 14 days):	Undetectable - 0.087	Undetectable - 0.21
Tanner Stage II (11.5 years):	Undetectable - 14.99	Undetectable - 0.36
Tanner Stage III (13.6 years):	2.25 - 27.00	Undetectable - 0.82
Tanner Stage IV (15.1 years):	6.24 - 26.45	Undetectable - 0.92
Tanner Stage V (18.0 years):	6.51 - 30.50	0.16 - 1.32

High amounts of testosterone in the body can lead to a lower sperm count.

Low testosterone concentrations can be caused by testicular failure (primary hypogonadism) or inadequate stimulation by pituitary gonadotropins (secondary hypogonadism).

Sample Type : Serum

End of Report

Dr. Adley Mark Fernandes
M.D (Pathology)
Pathologist

Gyoma V. Shah
Dr. Vyoma V Shah
M.D (Pathology)
Clinical Pathologist

ANJUMOL D V
ANJUMOL D V
Laboratory Technologist
Printed on: 27/02/2025 00:15

This is an electronically authenticated report

Page 2 of 4

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.





BML531241

Laboratory Investigation Report

Name	: Mr. SRDAN VIROVAC	Ref No.	: 37308
DOB	: 29/05/1989	Sample No.	: 2502544239
Age / Gender	: 35 Y / Male	Collected	: 26/02/2025 18:00
Referred by	: CITICARE MEDICAL CENTER	Registered	: 26/02/2025 23:21
Centre	: CITICARE MEDICAL CENTER	Reported	: 27/02/2025 00:09

TUMOUR MARKER

Test	Result	Flag	Unit	Reference Range	Methodology
PSA TOTAL (PROSTATE SPECIFIC ANTIGEN, TOTAL)	0.598		ng/mL	< 1.4 Please note change in method and reference range. Source: Roche Cobas Elecsys IFU.	ECLIA

INTERPRETATION NOTES :

Increased level can be seen in case of prostatitis, benign prostatic hyperplasia (BPH), urethral or prostatic trauma.
Decreased level can be seen in case of Surgical castration or medical castration. Drugs like Finasteride and dutasteride (5- α reductase inhibitors) can reduce PSA level.

When Total PSA is in the range of 4.0 - 10.0 ng/mL, a free:total PSA ratio $\leq$ 0.10 indicates 49% - 65% risk of prostate cancer depending on age; a free:total PSA ratio $>$ 0.25 indicates a 9% - 16% risk of prostate cancer depending on age.

Based on free:total PSA ratio, the percent probability of finding prostate cancer on a needle biopsy by age in years:

Free:total PSA ratio: $\leq$ 0.10

50 - 59 years: 49.2%

60 - 69 years: 57.5%

= or $>$ 70 years: 64.5%

Free:total PSA ratio: 0.11 - 0.18

50 - 59 years: 26.9%

60 - 69 years: 33.9%

= or $>$ 70 years: 40.8%

Free:total PSA ratio: 0.19 - 0.25

50 - 59 years: 18.3%

60 - 69 years: 23.9%

= or $>$ 70 years: 29.7%

Free:total PSA ratio: $>$ 0.25

50 - 59 years: 9.1%

60 - 69 years: 12.2%

= or $>$ 70 years: 15.8%

Source: Roche IFU.

The measured value of a patient's sample can vary depending on the testing procedure used. If there is a change in the assay procedure used while monitoring therapy, then the values obtained upon changing over to the new procedure must be confirmed by parallel measurements with both

Dr. Adley Mark Fernandes

M.D (Pathology)

Pathologist

Dr. Vyoma V Shah

M.D (Pathology)

Clinical Pathologist

This is an electronically authenticated report

Page 3 of 4




ANJUMOL D V

Laboratory Technologist

Printed on: 27/02/2025 00:15

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.





Laboratory Investigation Report

Name	: Mr. SRDAN VIROVAC	Ref No.	: 37308
DOB	: 29/05/1989	Sample No.	: 2502544239
Age / Gender	: 35 Y / Male	Collected	: 26/02/2025 18:00
Referred by	: CITICARE MEDICAL CENTER	Registered	: 26/02/2025 23:21
Centre	: CITICARE MEDICAL CENTER	Reported	: 27/02/2025 00:09


TUMOUR MARKER

Test	Result	Flag	Unit	Reference Range	Methodology
------	--------	------	------	-----------------	-------------

methods.

Sample Type : Serum

End of Report



Dr. Adley Mark Fernandes
M.D (Pathology)
Pathologist

Dr. Vyoma V Shah
M.D (Pathology)
Clinical Pathologist

ANJUMOL D V
Laboratory Technologist
Printed on: 27/02/2025 00:15

This is an electronically authenticated report

Page 4 of 4

Test result pertains only to the sample tested and to be interpreted in the light of clinical history. These tests are accredited under ISO 15189:2012 unless specified by (^). Test marked with # is performed in an accredited referral laboratory.

